Pronova BioPharma hosts Capital Markets Day
(Thomson Reuters ONE) -
Lysaker, Norway, 16 June 2011: Pronova BioPharma management will today present
the Group's strategic priorities at its Capital Markets Day.
Today's presentations will explore Pronova BioPharma's plans to extend its
manufacturing advantages with a target of increasing yields by 50 percent by the
end of 2014 compared to 2009 levels.
Together with its partners Abbott, Takeda and Ferrer, Pronova BioPharma also
plans to further increase the growth potential of Omacor(®), including entering
a number of important new markets with the product over the next three years.
Pronova BioPharma will provide an update on its R&D strategy, including pre-
clinical results of PRC-4016, a new chemical entity for the treatment of mixed
dyslipidemia. The Company has issued a separate press release today with more
details on PRC-4016, including plans to initiate clinical trials.
The complete Capital Markets Day presentation can also be found
onwww.pronova.com. A webcast will be made available following the event.
----------ends------------
Pronova BioPharma is a global leader in research, development and manufacture of
lipid therapies derived from nature.
Omacor®, also known as Lovaza(TM) in the US market, and Zodin®, Seacor®,
Esapent®, and Eskim® elsewhere, is the first commercialised product developed
from Pronova BioPharma's active pharmaceutical ingredient (API).
It is also the first and only EU and U.S. FDA-approved Omega 3-derived
prescription drug. Pronova BioPharma estimates that 1.4 million cardiovascular
patients, with high elevated levels of triglycerides and/or having suffered a
heart attack, are currently on a prescription for one of the branded products
containing its API.
Marketing and distribution of Pronova BioPharma's key product is currently
licensed to both local and global pharmaceutical companies. In 2009, the product
reached blockbuster status with sales over USD 1 billion in the current 8 major
markets and in 2010 it grew a further 19 percent to USD 1 260 million in 2010,
according to IMS Health. It is currently marketed in 56 countries with potential
launch in a further 30 countries.
Pronova BioPharma is developing several new, patentable lipid derivatives. The
most advanced Lipid Derived Pharmaceutical programme is in the area of
dyslipidemia, the abnormal concentration of lipids or lipoproteins in the
blood.
Pronova BioPharma's headquarters are located at Lysaker in Norway, while
production takes place in manufacturing facilities at Sandefjord in Norway and
in Kalundborg, Denmark. The company's shares are listed on Oslo Børs with the
ticker code PRON.
For further information contact:
Hamed Brodersen, VP Investor Relations and Communications Tel:
+47 40 46 81 10
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
Pronova BioPharma CMD 2011:
http://hugin.info/137506/R/1523838/459801.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pronova BioPharma ASA via Thomson Reuters ONE
[HUG#1523838]
Unternehmensinformation / Kurzprofil:
Datum: 16.06.2011 - 08:01 Uhr
Sprache: Deutsch
News-ID 55604
Anzahl Zeichen: 3988
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 314 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pronova BioPharma hosts Capital Markets Day"
steht unter der journalistisch-redaktionellen Verantwortung von
Pronova BioPharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
